93 related articles for article (PubMed ID: 18046889)
21. The interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant.
Sadowska AM; van Overveld FJ; Górecka D; Zdral A; Filewska M; Demkow UA; Luyten C; Saenen E; Zielinski J; De Backer WA
Respir Med; 2005 Feb; 99(2):241-9. PubMed ID: 15715193
[TBL] [Abstract][Full Text] [Related]
22. Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD.
De Benedetto F; Aceto A; Dragani B; Spacone A; Formisano S; Pela R; Donner CF; Sanguinetti CM
Pulm Pharmacol Ther; 2005; 18(1):41-7. PubMed ID: 15607126
[TBL] [Abstract][Full Text] [Related]
23. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study.
Moretti M; Bottrighi P; Dallari R; Da Porto R; Dolcetti A; Grandi P; Garuti G; Guffanti E; Roversi P; De Gugliemo M; Potena A;
Drugs Exp Clin Res; 2004; 30(4):143-52. PubMed ID: 15553660
[TBL] [Abstract][Full Text] [Related]
24. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease.
Dekhuijzen PN
Eur Respir J; 2004 Apr; 23(4):629-36. PubMed ID: 15083766
[TBL] [Abstract][Full Text] [Related]
25. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial).
Malerba M; Ponticiello A; Radaeli A; Bensi G; Grassi V
Pulm Pharmacol Ther; 2004; 17(1):27-34. PubMed ID: 14643168
[TBL] [Abstract][Full Text] [Related]
26. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
Poole PJ; Black PN
Cochrane Database Syst Rev; 2003; (2):CD001287. PubMed ID: 12804402
[TBL] [Abstract][Full Text] [Related]
27. Mucoactive drugs for asthma and COPD: any place in therapy?
Rogers DF
Expert Opin Investig Drugs; 2002 Jan; 11(1):15-35. PubMed ID: 11772318
[TBL] [Abstract][Full Text] [Related]
28. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease.
Kasielski M; Nowak D
Respir Med; 2001 Jun; 95(6):448-56. PubMed ID: 11421501
[TBL] [Abstract][Full Text] [Related]
29. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.
Pauwels RA; Buist AS; Calverley PM; Jenkins CR; Hurd SS;
Am J Respir Crit Care Med; 2001 Apr; 163(5):1256-76. PubMed ID: 11316667
[No Abstract] [Full Text] [Related]
30. Economic burden of chronic obstructive pulmonary disease. Impact of new treatment options.
Friedman M; Hilleman DE
Pharmacoeconomics; 2001; 19(3):245-54. PubMed ID: 11303413
[TBL] [Abstract][Full Text] [Related]
31. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review.
Stey C; Steurer J; Bachmann S; Medici TC; Tramèr MR
Eur Respir J; 2000 Aug; 16(2):253-62. PubMed ID: 10968500
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis.
Grandjean EM; Berthet PH; Ruffmann R; Leuenberger P
Pharmacol Res; 2000 Jul; 42(1):39-50. PubMed ID: 10860633
[TBL] [Abstract][Full Text] [Related]
33. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.
Burge PS; Calverley PM; Jones PW; Spencer S; Anderson JA; Maslen TK
BMJ; 2000 May; 320(7245):1297-303. PubMed ID: 10807619
[TBL] [Abstract][Full Text] [Related]
34. Induced sputum of patients with chronic obstructive pulmonary disease (COPD) contains adhesion-promoting, therapy-sensitive factors.
van Overveld FJ; Vermeire PA; De Backer WA
Inflamm Res; 2000 Jan; 49(1):8-13. PubMed ID: 10778915
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials.
Grandjean EM; Berthet P; Ruffmann R; Leuenberger P
Clin Ther; 2000 Feb; 22(2):209-21. PubMed ID: 10743980
[TBL] [Abstract][Full Text] [Related]
36. N-isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis.
Ekberg-Jansson A; Larson M; MacNee W; Tunek A; Wahlgren L; Wouters EF; Larsson S
Eur Respir J; 1999 Apr; 13(4):829-34. PubMed ID: 10362048
[TBL] [Abstract][Full Text] [Related]
37. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant.
Collet JP; Shapiro P; Ernst P; Renzi T; Ducruet T; Robinson A
Am J Respir Crit Care Med; 1997 Dec; 156(6):1719-24. PubMed ID: 9412546
[TBL] [Abstract][Full Text] [Related]
38. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment.
De Flora S; Grassi C; Carati L
Eur Respir J; 1997 Jul; 10(7):1535-41. PubMed ID: 9230243
[TBL] [Abstract][Full Text] [Related]
39. Attenuation of oxidant/antioxidant imbalance during treatment of exacerbations of chronic obstructive pulmonary disease.
Rahman I; Skwarska E; MacNee W
Thorax; 1997 Jun; 52(6):565-8. PubMed ID: 9227727
[TBL] [Abstract][Full Text] [Related]
40. Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary disease.
Rahman I; MacNee W
Thorax; 1996 Apr; 51(4):348-50. PubMed ID: 8733482
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
